more

Agenus (AGEN)

(Delayed Data from NSDQ)

$10.78 USD

+0.08 (0.75%)

Updated May 15, 2024 04:00 PM ET

After-Market: $10.74 -0.04 (-0.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum D VGM

Industry Rank:

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3

by Zacks Equity Research Published on November 02,2017

Epizyme (EPZM) posted narrower-than-expected loss in the third quarter of 2017. It plans to meet the FDA to begin the registration strategy for its lead pipeline candidate, tazemetostat, in the next quarter.

Zoetis (ZTS) Beats on Q3 Earnings & Sales, Ups 2017 View

by Zacks Equity Research Published on November 02,2017

Zoetis (ZTS) reported impressive third-quarter results beating estimates on both counts. Revenues were driven by strong demand for companion animal products worldwide.

Geron (GERN) Q3 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research Published on November 02,2017

Geron's (GERN) loss per share in the third quarter was narrower than expected. However, revenues missed estimates. Imetelstat remains in focus.

Sucampo (SCMP) Beats on Q3 Earnings & Revenues, Ups '17 View

by Zacks Equity Research Published on November 02,2017

Sucampo Pharmaceuticals' (SCMP) Amitizia recorded strong sales in the United States and Japan, which drove the company's top line in Q3. The company is also working on expanding its Amitizia's label.

Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store?

by Zacks Equity Research Published on November 02,2017

Horzion Pharma's (HZNP) primary care business is under pressure and we expect earnings to disappoint in the third quarter.

Is a Beat in Store for Ionis (IONS) This Earnings Season?

by Zacks Equity Research Published on November 01,2017

Ionis Pharmaceuticals (IONS) earned $50 million in milestone payments from Biogen. Spinraza had a strong third quarter as announced by Biogen in its earnings results.

Novo Nordisk (NVO) Tops Q3 Earnings Estimates, Lags Sales

by Zacks Equity Research Published on November 01,2017

Novo Nordisk A/S (NVO) reported third-quarter 2017 earnings of 63 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 58 cents. In fact, the reported figure was ahead of 57 cents earned a year ago.

Dr. Reddy's (RDY) Q2 Earnings and Revenues Decline Y/Y

by Zacks Equity Research Published on November 01,2017

Dr. Reddy's (RDY) earnings declined year over year but revenues increased on a year-over-year basis. The company remains focused on launching new products.

What to Expect from Keryx (KERX) This Earnings Season?

by Zacks Equity Research Published on October 31,2017

Keryx (KERX) will focus on the label expansion of its only approved drug, Auryxia, during the third-quarter 2017 earnings call.

What's in Store for Intrexon (XON) This Earnings Season?

by Zacks Equity Research Published on October 31,2017

Intrexon (XON) will remain focused on its performance along with other developmental updates in the third quarter of 2017.

AGENPositive Net Change

Will Endocyte (ECYT) Disappoint This Earnings Season?

by Zacks Equity Research Published on October 31,2017

Endocyte (ECYT) plans to focus on its most promising programs like CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform and its pipeline candidate EC2629 in Q3.

Jazz Pharmaceuticals (JAZZ) Q3 Earnings: A Beat in Store?

by Zacks Equity Research Published on October 31,2017

Jazz Pharmaceuticals' (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q3, thanks to label expansion efforts. Also, other products look promising to lead to an earnings beat.

Is a Beat in the Cards for Mylan (MYL) This Earnings Season?

by Zacks Equity Research Published on October 31,2017

Mylan N.V. (MYL) is likely to beat results when it reports third-quarter results next week driven by newly launched generics.

What's in the Cards for Prothena (PRTA) in Q3 Earnings?

by Zacks Equity Research Published on October 31,2017

Investors focus should remain on pipeline updates when Prothena Corporation (PRTA) reports third-quarter results as it has no approved product in its portfolio.